

WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 11 juin 2024 09:14

Laboratory Information

Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Glanders
Address of laboratory:	22 rue Pierre et Marie Curie / Maisons-Alfort 94706
Tel.:	+33 1 49 77 26 86
E-mail address:	karine.laroucau@anses.fr
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Zientara Stéphan
Name (including Title and Position) of WOAHO Reference Expert:	Dr Laroucau Karine
Which of the following defines your laboratory? Check all that apply:	

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
CFT		11	159
ELISA		1	399
Direct diagnostic tests			
real-time PCR Complexe B. pseudomallei		0	48
real-time PCR B. mallei		0	48

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHO?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHO Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAHO MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Glanders positive serum	CFT	produced	-	500 µL	1	HUNGARY,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

Yes

NAME OF WOAHA MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
MALTA	2023-09-01	CFT, ELISA, PCR	44	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAHA MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
New antigens for glanders diagnosis	2022-2024	Search for new diagnosis antigens	Gratz University	AUSTRIA
Investigation around a melioidosis case in a goat farm	2023-2024	Comparison of serological tools/characterisation of the strain	DAVAR	NEW CALEDONIA
Serological screening of domestic animals: for melioidosis detection	2023-2024	to collect preliminary data	DAAF	FRANCE - FRENCH GUIANA

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHA?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

2

Singha H, Tuanyok A, Elschner M, Laroucau K, Mukhopadhyay C. Editorial: Glanders and melioidosis: one health model. *Front Vet Sci.* 2023 Oct 13;10:1303556. doi: 10.3389/fvets.2023.1303556. eCollection 2023. PMID: 37901106 Free PMC article. No abstract available.

Wagner GE, Berner A, Lipp M, Kohler C, Assig K, Lichtenegger S, Saqib M, Müller E, Trinh TT, Gad AM, Söffing HH, Ehrlich R, Laroucau K, Steinmetz I. Protein Microarray-Guided Development of a Highly Sensitive and Specific Dipstick Assay for Glanders Serodiagnostics. *J Clin Microbiol.* 2023 Jan 26;61(1):e0123422. doi: 10.1128/jcm.01234-22. Epub 2022 Dec 21. PMID: 36541753

b) International conferences:

3

Laroucau K, Wernery U. Glanders Epidemiology. *International Horse Movement in Asia and the Pacific - Webinar on Glanders, 30 August 2023*

Laroucau K, Wernery U. Diagnostic tests for glanders & role of WOAHP Reference Laboratories. *International Horse Movement in Asia and the Pacific - Webinar on Glanders, 30 August 2023*

Laroucau K, Wernery U. Melioidosis – a disease to consider. *International Horse Movement in Asia and the Pacific - Webinar on Glanders, 30 August 2023*

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHP Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	Accreditation by COFRAC

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CFT	COFRAC
ELISA	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

B. mallei and *B. pseudomallei* are covered by the French regulation ANSM (Highly Pathogenic Microorganisms and Toxins)(biosafety and biosecurity) - Inspections. Work in level 3 confined areas under the supervision of a risk manager (safety and security).

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

Yes

Title of event	Date	Location	Role (speaker, presenting poster,	Title of the work
----------------	------	----------	-----------------------------------	-------------------

	(mm/yy)		short communications)	presented
Webinar on Glanders - International Horse Movement in Asia and the Pacific	2023-08-30	visioconférence	Speaker	Glanders Epidemiology
Webinar on Glanders - International Horse Movement in Asia and the Pacific	2023-08-30	visioconférence	Speaker	Diagnostic tests for glanders & role of WOAHA Reference Laboratories
Webinar on Glanders - International Horse Movement in Asia and the Pacific	2023-08-30	visioconférence	Speaker	Melioidosis – a disease to consider

TOR10: NETWORK WITH WOAHA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAHA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOAHA REF. LABS/ ORGANISING WOAHA REF. LAB.
inter-laboratory study to further validate serological diagnostic capacity of ID Screen Glanders Double Antigen Multispecies ELISA (GLANDA ELISA) in comparison with CFT	Participant	7	FLI/Germany (organising WOAHA ref lab) Anses/France (participating WOAHA ref lab) CVRL/UAE(participating WOAHA ref lab)

26. Did your laboratory collaborate with other WOAHA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOAHA REFERENCE LABORATORIES
Alternative/Complementary CFT methods for glanders diagnosis	To develop and/or validate alternative/complementary CFT methods by sharing reagents and/or data	Anses/France (WOAHA ref lab) FLI/Germany (WOAHA ref lab) CVRL/UAE(WOAHA ref lab)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the Test	WOAHA Member Countries
Proficiency test organised by Vetqas (CFT)	participant	15	CFT	

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHA?

No

29. Additional comments regarding your report:

No